Literature DB >> 33912161

Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.

Jintao Zhang1,2, Chunyuan Zhao1,2,3, Wei Zhao1,2.   

Abstract

The global expansion of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the greatest public health challenges and imposes a great threat to human health. Innate immunity plays vital roles in eliminating viruses through initiating type I interferons (IFNs)-dependent antiviral responses and inducing inflammation. Therefore, optimal activation of innate immunity and balanced type I IFN responses and inflammation are beneficial for efficient elimination of invading viruses. However, SARS-CoV-2 manipulates the host's innate immune system by multiple mechanisms, leading to aberrant type I IFN responses and excessive inflammation. In this review, we will emphasize the recent advances in the understanding of the crosstalk between host innate immunity and SARS-CoV-2 to explain the imbalance between inflammation and type I IFN responses caused by viral infection, and explore potential therapeutic targets for COVID-19.
Copyright © 2021 Zhang, Zhao and Zhao.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; inflammation; innate immunity; type I interferons

Year:  2021        PMID: 33912161      PMCID: PMC8071932          DOI: 10.3389/fimmu.2021.633769

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  91 in total

1.  Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists.

Authors:  Sarah A Kopecky-Bromberg; Luis Martínez-Sobrido; Matthew Frieman; Ralph A Baric; Peter Palese
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

2.  Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.

Authors:  Mark J Cameron; Longsi Ran; Luoling Xu; Ali Danesh; Jesus F Bermejo-Martin; Cheryl M Cameron; Matthew P Muller; Wayne L Gold; Susan E Richardson; Susan M Poutanen; Barbara M Willey; Mark E DeVries; Yuan Fang; Charit Seneviratne; Steven E Bosinger; Desmond Persad; Peter Wilkinson; Larry D Greller; Roland Somogyi; Atul Humar; Shaf Keshavjee; Marie Louie; Mark B Loeb; James Brunton; Allison J McGeer; David J Kelvin
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

3.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 4.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  W Joost Wiersinga; Andrew Rhodes; Allen C Cheng; Sharon J Peacock; Hallie C Prescott
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

5.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.

Authors:  Rudragouda Channappanavar; Anthony R Fehr; Rahul Vijay; Matthias Mack; Jincun Zhao; David K Meyerholz; Stanley Perlman
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

Review 6.  NLRP3 Inflammasome-A Key Player in Antiviral Responses.

Authors:  Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

7.  Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus.

Authors:  Santhana G Devaraj; Nan Wang; Zhongbin Chen; Zihong Chen; Monica Tseng; Naina Barretto; Rongtuan Lin; Clarence J Peters; Chien-Te K Tseng; Susan C Baker; Kui Li
Journal:  J Biol Chem       Date:  2007-08-30       Impact factor: 5.157

8.  SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.

Authors:  Carly G K Ziegler; Samuel J Allon; Sarah K Nyquist; Ian M Mbano; Vincent N Miao; Constantine N Tzouanas; Yuming Cao; Ashraf S Yousif; Julia Bals; Blake M Hauser; Jared Feldman; Christoph Muus; Marc H Wadsworth; Samuel W Kazer; Travis K Hughes; Benjamin Doran; G James Gatter; Marko Vukovic; Faith Taliaferro; Benjamin E Mead; Zhiru Guo; Jennifer P Wang; Delphine Gras; Magali Plaisant; Meshal Ansari; Ilias Angelidis; Heiko Adler; Jennifer M S Sucre; Chase J Taylor; Brian Lin; Avinash Waghray; Vanessa Mitsialis; Daniel F Dwyer; Kathleen M Buchheit; Joshua A Boyce; Nora A Barrett; Tanya M Laidlaw; Shaina L Carroll; Lucrezia Colonna; Victor Tkachev; Christopher W Peterson; Alison Yu; Hengqi Betty Zheng; Hannah P Gideon; Caylin G Winchell; Philana Ling Lin; Colin D Bingle; Scott B Snapper; Jonathan A Kropski; Fabian J Theis; Herbert B Schiller; Laure-Emmanuelle Zaragosi; Pascal Barbry; Alasdair Leslie; Hans-Peter Kiem; JoAnne L Flynn; Sarah M Fortune; Bonnie Berger; Robert W Finberg; Leslie S Kean; Manuel Garber; Aaron G Schmidt; Daniel Lingwood; Alex K Shalek; Jose Ordovas-Montanes
Journal:  Cell       Date:  2020-04-27       Impact factor: 41.582

Review 9.  Coronavirus virulence genes with main focus on SARS-CoV envelope gene.

Authors:  Marta L DeDiego; Jose L Nieto-Torres; Jose M Jimenez-Guardeño; Jose A Regla-Nava; Carlos Castaño-Rodriguez; Raul Fernandez-Delgado; Fernando Usera; Luis Enjuanes
Journal:  Virus Res       Date:  2014-08-02       Impact factor: 3.303

10.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.

Authors:  Canrong Wu; Yang Liu; Yueying Yang; Peng Zhang; Wu Zhong; Yali Wang; Qiqi Wang; Yang Xu; Mingxue Li; Xingzhou Li; Mengzhu Zheng; Lixia Chen; Hua Li
Journal:  Acta Pharm Sin B       Date:  2020-02-27       Impact factor: 11.413

View more
  5 in total

Review 1.  Exposing the Two Contrasting Faces of STAT2 in Inflammation.

Authors:  Philip Duodu; Geohaira Sosa; Jorge Canar; Olivia Chhugani; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2022-07-25       Impact factor: 3.657

2.  Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.

Authors:  Federica Frasca; Mirko Scordio; Letizia Santinelli; Lucia Gabriele; Orietta Gandini; Anna Criniti; Alessandra Pierangeli; Antonio Angeloni; Claudio M Mastroianni; Gabriella d'Ettorre; Raphael P Viscidi; Guido Antonelli; Carolina Scagnolari
Journal:  Eur J Immunol       Date:  2022-04-28       Impact factor: 6.688

3.  Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice.

Authors:  Ana C Puhl; Giovanni F Gomes; Samara Damasceno; Ethan J Fritch; James A Levi; Nicole J Johnson; Frank Scholle; Lakshmanane Premkumar; Brett L Hurst; Felipe Lee-Montiel; Flavio P Veras; Sabrina S Batah; Alexandre T Fabro; Nathaniel J Moorman; Boyd L Yount; Rebekah J Dickmander; Ralph S Baric; Kenneth H Pearce; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Sean Ekins
Journal:  ACS Omega       Date:  2022-08-29

Review 4.  Human genetic basis of severe or critical illness in COVID-19.

Authors:  Xiao-Shan Ji; Bin Chen; Bi Ze; Wen-Hao Zhou
Journal:  Front Cell Infect Microbiol       Date:  2022-09-20       Impact factor: 6.073

5.  High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals.

Authors:  Jeremy W Prokop; Nicholas L Hartog; Dave Chesla; William Faber; Chanise P Love; Rachid Karam; Nelly Abualkheir; Benjamin Feldmann; Li Teng; Tamara McBride; Mara L Leimanis; B Keith English; Amanda Holsworth; Austin Frisch; Jacob Bauss; Nathisha Kalpage; Aram Derbedrossian; Ryan M Pinti; Nicole Hale; Joshua Mills; Alexandra Eby; Elizabeth A VanSickle; Spencer C Pageau; Rama Shankar; Bin Chen; Joseph A Carcillo; Dominic Sanfilippo; Rosemary Olivero; Caleb P Bupp; Surender Rajasekaran
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.